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A B S T R A C T
Diabetes is an increasing worldwide problem leading to major associated health issues and increased
health care costs. In 2012, 9.3% of the American population was affected by diabetes, according to the
American Diabetes Association, with 1.7 million of new cases since during the year (www.diabetes.org).
Proteome initiatives can provide a deeper understanding of the biology of this disease and help develop
more effective treatments. The collaborative effort of the Human Diabetes Proteome Project (HDPP)
brings together a wide variety of complementary resources to increase the existing knowledge about
both type 1 and type 2 diabetes and their related complications. The goals are to identify proteins and
protein isoforms associated with the pathology and to characterize underlying disease-related pathways
and mechanisms. Moreover, a considerable effort is being made on data integration and network biology.
Sharing these data with the scientiﬁc community will be an important part of the consortium. Here we
report on: the content of the HDPP session held at the 12th HUPO meeting in Yokohama; recent
achievements of the consortium; discussions of several HDPP workshops; as well as future HDPP
directions as discussed at the 13th HUPO congress in Madrid, with a special attention given to the lists of
prioritized, diabetes-related proteins and the proteomic means to study them.
Abbreviations: HUPO, Human Proteome Organization; HPP, human proteome project; B/D-HPP, biology/disease-human proteome project; C-HPP, chromosome-centric
human proteome project; T1D, type 1 diabetes; T2D, type 2 diabetes; SRM, selected reaction monitoring.
Contents lists available at ScienceDirect
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The pathology of diabetes is an increasing concern in both
industrialized and developing countries, and is therefore of major
importance for the life science community. The Human Diabetes
Proteome Project was created to gather worldwide experienced
professionals in the ﬁeld, aiming at joining the efforts to better
understand the pathology and its associated complications.
Meetings and workshops are organized throughout the year by
the different partners, to promote sharing of scientiﬁc information
concerning projects associated to the initiative. They are also used
to discuss and decide on the group’s objectives. The HUPO meeting
in Yokohama (September, 2013), the HDPP workshop in Uppsala
(April, 2014) and the HUPO meeting in Madrid (October, 2014)
were the most recent occasions for the HDPP partner, as well as
other scientists with particular interest in the ﬁeld, to share their
expertise and exchange their recent ﬁndings. We describe here the
work accomplished by the partners during the year 2014, as well as
the future directions intended by the consortium.
2. 4th HUPO diabetes workshop, Yokohama
Yokohama (Japan) hosted the 12th Human Proteome Organi-
zation (HUPO) annual world congress. HUPO congresses enable
researchers involved in the Human Proteome Project (HPP)
initiative to share their experiences, to network, and to advance
their scientiﬁc research and collaborations. During the
Biology/Disease Human Proteome Project (B/D-HPP) session led
by Gilbert S. Omenn and Ruedi Aebersold, scope and objectives of
the initiative were outlined: all B/D-HPP initiatives should
follow the HPP requirements, in that they are based on three
main pillars: the antibody pillar, the mass spectrometry (MS)
pillar and the knowledge-based pillar [1–3]. Additionally, the
importance of comprehensive network-based and systems-level
approaches to decipher important disease-related mechanisms
was emphasized.
The 4th Human Diabetes Proteome Project (HDPP) workshop at
HUPO 2013 attracted about 90 attendees. The overall initiative was
re-introduced and related themes were debated. Jean-Charles
Sanchez, HDPP chair in 2013, presented the HDPP roadmap,
website (www.hdpp.info), as well as the creation of the ﬁrst
“priority list” of proteins to be studied by the consortium
(described in [4] “1000 diabetes-protein list”).
HDPP aims at collecting various datasets from diverse origins,
and at integrating them to perform network biology in order to
maximize the conversion from data to knowledge. These resources
include proteomic data from islets of Langerhans, beta-cells and
blood; plus other tissues and ﬂuids as described by Topf et al. [4].
Preferably, human samples will be analyzed, supplemented by data
from other species, such as rat or mouse.
Several partners presented their projects at this workshop.
These presentations included:
 An alternative to selected-reaction monitoring (SRM) for
biomarker discovery in islets and subsequent quantiﬁcation in
plasma (Domitille Schvartz, Univ. Geneva, Switzerland).
The B/D-HPP aims also include the MS-based pillar, specifying
the need for qualitative and quantitative measurements of the
proteins of interest by mass spectrometry. The Translational
Biomarker Group in Geneva developed an isobaric Tandem Mass
Tag (TMT)-based method to identify and quantify proteins that are
tissue-speciﬁc and also circulate in human blood, the latter being
the most important bioﬂuid for human biomarker discovery/
validation. This method was applied to human islets and enabled
the quantiﬁcation of 729 human islet proteins in plasma, many ofthem having estimated plasma concentrations below 1 ng/ml
(Human Plasma Proteome Database [5]; http://www.plasmapro-
teomedatabase.org/). Among these proteins, 449 are part of the
10000-HDPP list, and 81 of them were detected for the ﬁrst time in
plasma (with reference to the human plasma database). This
innovative approach presents a useful alternative to SRM for the
detection, quantiﬁcation and monitoring of proteins of interest in
complex body ﬂuids such as plasma.
 A systems omics perspective of diabetes (Michael Snyder,
Stanford Univ., USA)
The Stanford group presented results of multi-omic longitudi-
nal proﬁling (genomics, transcriptomics, proteomics, metabolo-
mics, autoantibody proﬁles, metagenomics (i.e., microbiome) of a
single individual over 3.5 years as well as plans to increase the
study to a cohort of 60 individuals for three years. This
longitudinal, n = 1 multi-omics approach revealed health trajecto-
ries and early deviations thereof.
 Beta-cell function in juvenile obesity and type 2 diabetes
(Peter Bergsten, Uppsala Univ., Sweden).
Development of type 2 diabetes is connected to obesity. With
growing numbers of overweight and obese children, the incidence
of type 2 diabetes early in life is increasing dramatically. The
progression towards overt type 2 diabetes reﬂects that the function
of the insulin-producing beta-cell is impaired in those cases. The
group in Uppsala is focused on deﬁning mechanisms for this beta-
cell impairment through the study of both isolated human islets at
the cellular level and patient samples obtained from obese and
normal weight children.
 Beta-cells and mitochondrial function (Martin Kussmann, Nestlé
Institute of Health Sciences, Switzerland)
In the frame of the HPP MS pillar, the Nestlé Institute of Health
Sciences in Lausanne has partnered with Thermo Fisher Scientiﬁc
to advance technology and leverage this to the characterization
and quantiﬁcation of mitochondrial proteomes. Mitochondria
were isolated from the rat livers. Ten-plex TMT was used for
relative protein quantiﬁcation between 18 experimental condi-
tions. The samples were analyzed with reversed-phase liquid
chromatography (RP-LC), coupled to either a hybrid linear ion
trap-Orbitrap (LTQ-OT) Elite or an OT Fusion Tribrid mass
spectrometer [6]. While both MS platforms roughly delivered
the same proteome coverage, i.e., about 10000 protein identiﬁca-
tions (93% overlap), signiﬁcant differences at the quantiﬁcation
level were obtained: using MS/MS/MS [7], the OT Fusion Tribrid
usually provided larger and more discrete quantitative protein fold
ratios with respect to the LTQ-OT Elite that employed MS/MS. More
data points and less missing protein quantitative values were
obtained with the OT Fusion Tribrid instrument.
3. From Yokohama to Madrid
3.1. From the 1000-HDPP to the 100-HDPP and the 25-HDPP
One of the prime requirements from HUPO and HPP for the B/D-
HPP initiatives was to generate priority lists of biology/disease-
relevant proteins and render them publicly available. This was
achieved by the HDPP consortium during its ﬁrst year of existence
(2013), by creating the 10000-HDPP protein list, containing to date
10398 proteins considered to be of high interest in the ﬁeld of
diabetes, as well as their corresponding neXtProt, Human Protein
Atlas and PeptideAtlas entries [8–10]. This list was published in the
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portal: http://www.hdpp.info/. Additionally, these proteins were
marked in the PeptideAtlas with a speciﬁc mention of the “HDPP
initiative”. From the 10000-HDPP, several sub-lists were created
within the consortium: the 100-HDPP (Supplemental data),
encompassing a selection of 100 proteins under consideration
for biomarker development for diabetes and related conditions.
This list is based on the literature and on expert recommendations.
The 5th HDPP workshop in Uppsala in April 2014 was the occasion
to generate an even more condensed list of 25 top-priority HDPP
proteins, derived from the 100-HDPP, and representing the 25 top
candidate biomarkers for diabetes-related conditions and their
diagnostics in plasma. These proteins were selected based on
collective expertise, discussions between the partners during the
various workshops, and extended bibliographic research (Table 1).
Using Ingenuity Pathway Analysis (http://www.ingenuity.com),
the Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING [11]), and Protein Analysis Through Evolutionary Rela-
tionships (PANTHER) [12,13]; http://david.abcc.ncifcrf.gov/) analy-
ses of the collected lists were made by the Univ. of Turku, providing
an overview of the functional associations between these proteins.
This 25-HDPP shortlist includes insulin; four insulin receptor
proteins; and proteins involved in glucose and lipid homeostasis.
The key pathways included type 2 diabetes, insulin signaling,
adipocytokine signaling, as well as sugar and carbohydrate
metabolism (Table 2). STRING provided a good visualization of
the 25-HDPP (Fig. 1). To simplify the IPA analyses of the 25-HDPP,
the 1000-HDPP was used as background; these analyses under-
lined the associations and importance of STAT3 (included in the
1000) in pathways related to immune response (Fig. 2). For the
100-HDPP, IPA presented some clear and distinct networks (Fig. 3).
The network in Fig. 3, described as lipid metabolism, molecular
transport, small molecule biochemistry, includes a number of the
apolipoproteins (e.g., APOA1, APOA2, APOA etc.) and some
interleukins (IL1 and IL2). In addition to NFkB, the peroxisome
proliferator-activated receptors (PPARD, PPARG, PPARA), retinoic
acid receptor (RXRA) and hepatocyte nuclear factors (HNF) occupy
nodal positions. The Ingenuity canonical pathways of LXR/RXR
activation and FXR/RXR activation were the most signiﬁcantTable 1
The 25-HDPP. List of the top-25 proteins considered to be potential plasma
biomarkers for diabetes-related disorders.
Name Gene name neXtProt
Adiponectin ADIPOQ NX_Q15848
Carboxypeptidase E CPE NX_P16870
Glucagon GCG NX_P01275
Glucagon receptor GCGR NX_P47871
Glucokinase GCK NX_P35557
Glucagon-like peptide 1 receptor GLP1R NX_P43220
Hexokinase-1 HK1 NX_P19367
Hexokinase-2 HK2 NX_P52789
Hexokinase-3 HK3 NX_P52790
Islet amyloid polypeptide IAPP NX_P10997
Insulin INS NX_P01308
Insulin receptor INSR NX_P06213
Insulin receptor substrate 1 IRS1 NX_P35568
Insulin receptor substrate 2 IRS2 NX_Q9Y4H2
Insulin receptor substrate 4 IRS4 NX_O14654
Leptin LEP NX_P41159
Leptin receptor LEPR NX_P48357
Apolipoprotein(a) LPA NX_P08519
Lipoprotein lipase LPL NX_P06858
Pro-neuropeptide Y NPY NX_P01303
Pancreatic prohormone PPY NX_P01298
Somatostatin SST NX_P61278
Mitochondrial uncoupling protein 1 UCP1 NX_P25874
Mitochondrial uncoupling protein 2 UCP2 NX_P55851
Mitochondrial uncoupling protein 3 UCP3 NX_P55916(analysis of the 100-HDPP, Table 3), indicating the participation of
almost 20 proteins. Farnesoid X receptor (FXR) and liver X receptor
(LXR) activation are both involved with cholesterol homeostasis.
LXR, in particular is also involved with glucose and fatty acid
homeostasis, whereas the primary role of FXR concerns suppres-
sion of cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting
enzyme in bile acid synthesis from cholesterol. Since insulin is a
component of this pathway, the Ingenuity canonical pathways
presented for the HDPP25 also included FXR/RXR activation.
Additional details of the annotation and networks are provided as
Supplemental data.
3.2. The islet proteome database
3.2.1. Update on the database
Human islets are of central interest for type 1 and type
2 diabetes research, as they are a key functional unit for insulin
production and secretion, and glucose homeostasis. Many efforts
have already been made to characterize the human islet proteome
and gain insight into the islet-related mechanisms involved in the
development of diabetes [14,15]. We are building the largest
human islet proteome database, constructed from two bottom-up
proteomic studies. In the ﬁrst study by Metz et al. the authors used
two complementary proteolytic digestion protocols. They frac-
tionated each sample with strong cation exchange, followed by
RP-LC, and analyzed the peptides on a linear ion trap MS. MS/MS
data analysis was done with SEQUEST, resulting in highly conﬁdent
identiﬁcation of 30365 proteins with at least two unique peptides
sequenced per protein (and 40925 with one unique peptide) [16]. In
the second study by Topf et al. digested peptides were fractionated
by off-gel electrophoresis followed by RP-LC and analyzed by
gas-phase fractionation MS. The authors identiﬁed 30799 proteins
with at least two unique peptides and a FDR < 1% (50309 with one
unique peptide) [4]. These two protein lists were combined into a
set of 40494 human islet proteins with two unique peptides
sequenced per parent protein. In addition to their close similarity,
the combination of the results from the two data sets signiﬁcantly
increased the overall number of entries in the reference database
(Supplementary data). The islet proteins are equally distributed
across all 24 human chromosomes, representing approximatively
30% of all protein coding genes for each chromosome, except for
chromosome Y (Supplementary data).
In order to clarify whether this new islet proteome database
contains yet unidentiﬁed proteins, we searched the neXtProt
database for proteins in our database whose existence was not yet
conﬁrmed at the protein level. neXtProt, the knowledge-based
pillar of HDPP, deﬁnes protein existence based on criteria
established by UniProtKB/Swiss-Prot in 2007 [9]. Five levels of
evidence have been deﬁned: (1) evidence at protein level (e.g.,
identiﬁcation by MS, detection by antibodies, sequence by Edman
degradation, or tridimensional structure resolved); (2) evidence at
transcript level (e.g., ESTs or full length mRNA); (3) inferred by
homology (strong sequence similarity to known proteins in related
species); (4) predicted and (5) uncertain (e.g., sequences that are
likely the products of erroneous translations of pseudogenes).
neXtProt applies the same criteria, but since it contains more MS
data there is evidence for a larger number of proteins.
According to the neXtProt database, 34 of the proteins in our
islet proteome database have to date only been identiﬁed at the
transcript level. Table 4 describes these speciﬁc proteins and their
chromosomal localization. This list will be spread into the scientiﬁc
community, targeting especially C-HPP initiatives, through the
HDPP website and the various congresses and workshops. This
work thus bridges with the C-HPP initiatives to target their
research of missing proteins across the various chromosomes [17].
Table 2
KEGG pathways associated with the 25-HDPP. The analysis was made using STRING, and a Bonferroni correction applied to the p-values calculated for the pathway
enrichment.
KEGG_pathway Protein count of 25 p-value (Bonferroni corrected)
hsa04930: Type II diabetes mellitus 9 1.0E-16
hsa04920: Adipocytokine signaling pathway 7 1.5E-10
hsa04910: Insulin signaling pathway 8 2.2E-10
hsa00524: Butirosin and neomycin biosynthesis 4 1.4E-09
hsa00052: Galactose metabolism 4 4.1E-06
hsa04960: Aldosterone-regulated sodium reabsorption 4 2.0E-05
hsa00520: Amino sugar and nucleotide sugar metabolism 4 4.8E-05
hsa00500: Starch and sucrose metabolism 4 5.7E-05
hsa00010: Glycolysis/gluconeogenesis 4 0.00013
hsa00051: Fructose and mannose metabolism 3 0.0018
hsa04973: Carbohydrate digestion and absorption 3 0.0024
hsa03320: PPAR signaling pathway 3 0.015
hsa04080: Neuroactive ligand-receptor interaction 4 0.048
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blood
Another project implicated in the HDPP initiative concerns the
characterization of speciﬁc post-translational modiﬁcations
(PTMs) associated to diabetes. Diabetic complications have been
proposed to occur through non-enzymatic modiﬁcation of proteins
by glucose, namely glycation, in various tissues, favoring, among
others, the occurrence of atherosclerosis, renal failure, retinopathy,
micro- and macro-angiopathy. Beside continuous advances in
treatment of the deleterious effects of hyperglycemia, aspirin was
shown to play a key role in the protection against the initial
glycation process and, also, to be associated to a decrease in
occurrence of cardiovascular events in high risk diabetic patients
[18,19]. A mutual inﬂuence between aspirin-acetylation and
protein glycation, was already proposed for human albumin [20]
and for several other proteins as well, but few studies are currently
available for complex samples with high dynamic ranges. For thisFig. 1. STRING analysis of the 25-HDPP proteins. Nodes are either colored (if they are d
predicted functional links, consist of up to eight lines: one colour for each type of evidpurpose, in vitro analysis of protein extracts from blood
fractionated plasma, erythrocytes (RBCs), leukocytes (WBCs) and
platelets (PLTs) were carried out using high resolution tandem
mass spectrometry coupled with a label-free approach, in order to
provide (1) qualitative data through the identiﬁcation of the
preferential acetylation and glycation sites, and (2) quantitative
information to evaluate the abundance of these PTMs. A total
number of 40, 33, 73 and 44 unique acetylated proteins were
identiﬁed in plasma, RBCs, PLTs and WBCs, respectively. On the
other hand, a total number of 75, 60, 87 and 45 unique glycated
proteins were identiﬁed in plasma, RBCs, PLTs and WBCs,
respectively. These data are available on the HDPP website.
Quantitative data were obtained for the majority of the identiﬁed
proteins, and a signiﬁcant effect in glycation and acetylation levels
was observed for most of them including apolipoproteins,
ﬁbrinogen and complement factors in plasma; different hemoglo-
bin subunits, carbonic anhydrase 1 and isoforms of peroxiredoxin
in RBCs; interleukin a-1, protein S100 isoforms andirectly linked to the input or white (nodes of a higher iteration/depth)). Edges, i.e.,
ence.
Fig. 2. Ingenuity pathway analysis of the HDPP proteins. Based on the 25-HDPP with a background of the 1000-HDPP (direct interactions only). The network identiﬁed is
described as carbohydrate metabolism, endocrine system disorders and metabolic disease. Red shading represents proteins in the 25-HDPP, grey other proteins in the 1000-
HDPP, and the uncoloured shapes are from proteins added by IPA.
Fig. 3. Ingenuity pathway analysis of the HDPP proteins. Based on the 100-HDPP. The brighter red shading represents proteins in the 25-HDPP (e.g., LEPR & INS).
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Table 3
The top Ingenuity canonical pathways associated with the 100-HDPP, giving an overview of the proteins associated with the LXR/RXR Activation and FXR/RXR Activation
pathways. The pathways involving IL-12 signalling and other cytokines are also highly signiﬁcant.
Ingenuity canonical pathways p-value Count Molecules
FXR/RXR activation 1.26E-25 18 PPARG, PPARA, APOE, IL1A, APOB, HNF1A, IL18, APOA1, FASN, APOC3, FOXA2, INS, FBP1,
IL1B, G6PC, RXRA, HNF4A, TNF, FOXA3
LXR/RXR activation 5.01E-24 19 APOE, IL1A, APOM, APOA4, APOB, LPA, APOA2, APOA5, IL6, RXRG, IL18, LDLR, APOA1,
APOC3, FASN, LPL, IL1B, RXRA, TNF, APOD
IL-12 signaling and production in macrophages 1.00E-21 18 PPARG, IFNG, APOE, APOM, APOA4, APOB, LPA, IL12A, IL10, APOA2, IL18, APOA1, IL12B,
APOC3, PIK3CB, RXRA, TNF, IL4, APOD
Role of cytokines in mediating communication
between immune cells
2.00E-18 12 IFNG, IL18, IL1A, IL12A, IL12B, IL2, IL10, IFNB1, IL1B, IL6, IL13, TNF, IL4
6 D. Schvartz et al. / Translational Proteomics 8 (2015) 1–7myeloperoxidase in WBCs; integrin a-IIb, P-selectin and thymosin
b-4 in PLTs (to cite few). These results strongly conﬁrm the
protective role of aspirin over protein glycation and in parallel
highlight new interesting features through which glycation may
inﬂuence aspirin-acetylation. In the near future we will use the
same analytical method to compare the extent of protein glycationTable 4
List of 34 human islet proteins known in neXtProt only at the transcript level.
Chromosome Uniprot neXtProt
1 (China) A6PVY3 NX_A6PV
Q5TZ20 NX_Q5T
Q5VU65 NX_Q5V
Q6XR72 NX_Q6X
2 (Switzerland) Q9UBK7 NX_Q9U
Q68DN1 NX_Q68
Q6ZRH9 NX_Q6Z
4 (Taiwan) O75795 NX_O757
P78426 NX_P784
5 (Netherlands) Q8NGU9 NX_Q8N
6 (Canada) Q29865 NX_Q29
Q8NA58 NX_Q8N
7 (Australia) Q96PB1 NX_Q96
O43374 NX_O43
Q96NL0 NX_Q96
Q99680 NX_Q99
9 (Korea) Q5TYW2 NX_Q5T
10 (USA) O95231 NX_O95
Q5W0B7 NX_Q5W
11 (Korea) Q8NGF8 NX_Q8N
Q96QZ0 NX_Q96
Q9Y2U2 NX_Q9Y
12 (India, Singapore, Taiwan, Thailand) Q5BKT4 NX_Q5B
Q9NQS5 NX_Q9N
15 (Brazil) Q8NG48 NX_Q8N
Q8NCU7 NX_Q8N
Q9UKL4 NX_Q9U
16 (Spain) P17538 NX_P175
P69849 NX_P698
17 (USA) P05496 NX_P054
21 (Canada) P58505 NX_P585
X (Japan) O15391 NX_O153
Q96DU9 NX_Q96
Q9NY87 NX_Q9Nand aspirin-mediated acetylation in non-diabetic control subjects
(HbA1c  6%) and in poorly controlled diabetic patients (HbA1c
 8%), before and after aspirin treatment, in order to provide
insights on the interplay exerted in vivo by aspirin and glucose at
protein level and, at the same time, offer an alternative
perspectives for the characterization of new potential markers Band First position Last position
Y3 q41 222910549 222924147
Z20 q44 248684916 248685964
U65 q21.3 153965161 154127592
R72 q41 219858769 220131989
BK7 q13 114384806 114400973
DN1 p23.3 27799389 27805588
RH9 q31.1 175200604 175202151
95 q13.2 69402902 69434245
26 q21.23 85413140 85419603
GU9 q15 94955782 94957846
865 p21.33 31228737 31232108
A58 q25.3 160221298 160241736
PB1 q21.3 94138531 94186331
374 q22.1 102220093 102257204
NL0 q21.12 87256864 87461611
680 q22.3 107110463 107116098
YW2 q13 67926761 67969840
231 q26.3 135050908 135055433
0B7 p12.33 18041218 18089855
GF8 p11.2 48238344 48239314
QZ0 q24.2 124481386 124490252
2U2 q13.1 65360326 65363467
KT4 p11.1 34175216 34182629
QS5 q13.13 54756229 54758271
G48 q26.3 101099574 101143435
CU7 q22.2 62359176 62363116
KL4 q14 35043233 35047166
38 q23.1 75252898 75258822
49 p13.11 16326352 16388668
96 q21.32 46970127 46973233
05 q22.3 47720095 47743789
91 p22.12 21874105 21876845
DU9 q21.31 90689594 90693583
Y87 q27.2 140335596 140336629
D. Schvartz et al. / Translational Proteomics 8 (2015) 1–7 7of glycemic control, besides the commonly used glycated
hemoglobin (HbA1c).
4. Madrid 2014 workshop
The international HDPP consortium is still growing and now
encompasses 23 partners. The 13th HUPO congress in Madrid,
Spain, was the opportunity for the key proteomic players in
diabetes research to meet for their 6th HDPP workshop, which has
been the follow up on the preceding HPP, C-HPP and B/D-HPP
meetings. It was the place to discuss the 25-HDPP proteins list and
its diffusion within the scientiﬁc community. This list was selected
as the starting point of the ﬁrst collaborative wet-lab project to be
executed by the consortium, namely to develop MS and/or
antibody-based assays to quantify these proteins systematically
across human diabetes studies. The importance of working with
panels of proteins was emphasized in the context of diabetes early
diagnostic and follow-up.
In addition to protein “priority lists” created so far in the
consortium, the workshop discussed future possibilities to provide
added value by including metabolites, lipids, PTMs or other
measurable biomolecules. Members of the consortium ﬁnally
accentuated the importance of data sharing across the community,
notably through scientiﬁc publications and the evolution of the
HDPP website.
5. Conclusions
The Human Diabetes Proteome Project focuses on two main
objectives: (i) to conduct comprehensive analysis of diabetes-
associated molecular networks; and (ii) to identify diagnostic/
prognostic proteins and isoforms associated with the pathology.
For the past two years the consortium has collected and
integrated datasets and is now rendering the related information
accessible for researchers in the ﬁeld. In parallel, priority lists
were generated to highlight the proteins of key importance and
relevance to diabetes research. According to the HPP guidelines,
efforts will be made in the future to make MS and/or antibody-
based assays available for the detection and quantiﬁcation of
these priority proteins as potential biomarkers for early disease
diagnostics and/or or monitoring.
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